Text Size: a  |   a 

Latest Tecfidera and Tysabri Data Suggest Treatments Improve MS Outcomes When Used Early

April 26, 2017

Although some patients refuse to use Tysabri for their multiple sclerosis (MS) treatment, research suggests that using Tecfidera and Tysabri at early disease stages improves outcomes and prevents disability development in relapsing multiple sclerosis (MS) patients. However, studies presented by Biogen at the American Academy of Neurology 2017 Annual Meeting in Boston, might challenge this view. They suggest that more potent disease modifying drugs should be used for later disease stages.

However, the new real world Tecfidera and Tyasbri data are available to challenge this. After multiple studies, results showed that those who initiated treatment, with these drugs, one year or sooner after the first symptoms appeared were more likely to experience disability improvement than those who started treatment later. Improvement was seen in 49.23% in those treated early, 38.1% in those who started treatment between one and five years, and 26.3% in those who started treatment after more than five years after symptom onset. On the other hand, researchers pointed out that Tysabri also reduced annualized relapse rates when treatment was started later.

Via MS News Today